Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection (R21)
Grant Amount: Unspecified.
The purpose of this Funding Opportunity Announcement (FOA) is to fill gaps in our understanding of (a) the pathogenic interactions between HIV and hepatitis viruses, (b) co-morbidities associated with HIV/hepatitis virus co-infection, and c) the effectiveness of interferon-free direct-acting antiviral drug regimens to treat HIV/HCV co-infection. This FOA is informed by priority areas in the 2011 HHS Action Plan, Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care and Treatment of Viral Hepatitis: http://www.hhs.gov/ash/initiatives/hepatitis/index.html.
Research should focus on HIV-infected adults, pregnant/postpartum women, adolescents, children, infants and sub-populations at highest risk for HBV or HCV co-infection. The R21 mechanism is intended to encourage new exploratory and developmental research projects. Applications for R21 awards should describe projects distinct from those supported through the traditional R01 mechanism. Applications submitted under this mechanism should be exploratory and novel. These studies should break new ground or extend previous discoveries toward new directions or applications.
National Institute of Allergy and Infectious Diseases National Institute on Drug Abuse Division of AIDS US Department of Health and Human Services Public Health Service Public Health Services National Cancer Institute National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Office of Communications National Institute of Mental Health National Institute on Alcohol Abuse and Alcoholism
City Agencies Colleges/Universities Commercial Organizations Community Based Organizations County Agencies Educational Organizations/Institutions Federal Government Agencies International Agencies IRS 501 (c)(3) Organizations Nonprofit Organizations Religious Organizations Schools State Agencies Tribal Organizations
Award Amount Notes
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.
Antiviral Drugs Hepatitis HIV Persons with HIV/Hepatitis Research Programs
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide (http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_General_Adobe_VerB.pdf), except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Companion Funding Opportunity: PAR-14-255, R01 Research Project Grant.
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.